FDA acceptance of Arcalyst sBLA puts Regeneron closer to gout market
This article was originally published in Scrip
Executive Summary
With last week's OK from the US FDA for Eylea (aflibercept) in hand, Regeneron Pharmaceuticals is hoping to soon market its first US-approved drug Arcalyst (rilonacept) for a second indication – preventing gout flares in patients initiating uric acid-lowering therapy.